Figure 6

Quantitation of Siglec-F ligands in airway epithelial cells and peribronchial inflammatory cells. Lung sections from non-OVA or chronic OVA challenged WT or Siglec-F deficient mice were immunostained with a Siglec-F-Fc or a control Fc. The number of peribronchial cells (Fig 6A), as well as the area of airway epithelial cells (Fig 6B) immunostaining positive for Siglec-F-Fc was quantitated by image analysis. OVA challenged WT mice had significantly increased numbers of peribronchial cells immunostaining positive with the Siglec-F-Fc (p = 0.0001*)(Fig 6A) and significantly increased levels of airway epithelial cell Siglec-F-Fc immunostaining compared to non-OVA challenged WT mice (p = 0.0001*)(Fig 6B). Siglec-F deficient mice challenged with OVA had significantly increased numbers of peribronchial cells immunostaining positive for Siglec-F-Fc compared to OVA challenged WT mice (p = 0.01^#)(Fig 6A), whereas airway epithelial Siglec-F-Fc immunostaining was similar in OVA challenged Siglec-F deficient and WT mice (Fig 6B)(n = 16 mice/group).